CClinicalTrials.gg
CompletedNCT04207996Updated Sep 29, 2026

Vagus Nerve Response in Gastroparesis Patients

An observational study in Gastroparesis, sponsored by Indiana University. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Indiana University · Observational

Updated Sep 29, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
45
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study aims to characterize how vagus nerve compound action potentials (CNAPs) conduct along the vagus nerve in gastroparetic patients receiving GES therapy using a flexible, non-invasive multielectrode array (MEA).

Read the detailed description

During Phase

1, in a small cohort of 5-10 gastroparetic patients receiving GES therapy, we will determine the optimal multielectrode array (MEA) recording electrode configuration (e.g., surface area covered and electrode density) for the noninvasive measurement of gastric electrical stimulation (GES) evoked compound nerve action potentials (CNAP) from the skin surface over the left and right cervical vagus nerve. During Phase 2, a study of 15-30 gastroparetic patients receiving GES therapy, we will use the optimal MEA configuration identified in Task 1 to measure and classify the vagal CNAP response signature (including the direction of travel and anatomical location of the strongest signal (e.g., to infer the anatomical course of the cervical vagus in each subject) with respect to subject-reported symptom scores via the 9-item Gastroparesis Cardinal Symptom Index (GCSI) survey. We will cross-reference these results with the preliminary results obtained with bipolar ECG electrodes.

Phase 1:

Subjects will complete a symptom survey questionnaire and Gastric Cardinal Symptom Index (GCSI) questionnaire. Two electrocardiography (ECG) electrodes will be placed on both sides of the neck overlying the area near the carotid pulse (which overlies the carotid artery in the neck on the side of your neck) where the vagus nerve is located.This is done in order to measure the vagal nerve electrical impulses in the neck (electrical signal travelling in the nerve).

Two ECG electrodes will be placed on each of the arms and one on the chest for measurement of electrocardiogram (ECG) ( a test to measure the electrical activity of your heart). Three ECG electrodes may be placed on the stomach to measure the electrical activity of the stomach.

After the placement of the electrodes, a 2-5 minute recording will be made.The GES device will be interrogated (data will be obtained) for the settings of the device and these will be recorded by the study team. After the recording, the electrodes will be removed from the neck and a newer kind of electrodes called as MEA (Multi electrode Array)) devices that contain multiple (tens to thousands of small electrodes) will be placed on either one, or both sides of the neck. This film will help capture the vagus signal from a large area and help define the path of the vagus nerve. After the placement of this film with small electrodes, another 2-5 minute recording will be made. The electrodes will then be removed and subject will be allowed to go home.

The total time required for Phase 1 will be approximately an hour (60 minutes).

Phase 2:

Subject will complete a symptom survey questionnaire and Gastric Cardinal Symptom Index (GCSI) questionnaire. Multiple electrodes (MEA) will be placed on either one or both sides of the neck. One ECG electrodes will be placed on each of the arms, and one on the chest for measurement of electrocardiogram (ECG). Three ECG electrodes will be placed on the stomach to measure the electrical activity of the stomach. After the placement of the electrodes a 2-5 minute recording will be made. The GES device will be interrogated (data will be obtained) for the settings and these will be recorded by the study team. With the GES stimulator on, a 2-5 minute recording will be made. Then, the GES stimulator will be reprogrammed to deliver the signal at 50% of the original power, and another 2-5 minute recording will be made. Then, the device will again be programmed to deliver the signal at 25% of the original power setting on the device. Another 2-5 minute recording will be made. After this, the device will be reprogrammed to the original settings. The electrodes will then be removed and subject will be allowed to go home.

The total time required for Phase 2 will be approximately an hour (60 minutes).

02

Conditions studied

  • Gastroparesis

Browse trials for

03

In context

Gastroparesis

307 studies on the registry are indexed under Gastroparesis; 68 are open to participants now.

This study's enrollment of 45 is below the median of 100 across 77 observational studies indexed under Gastroparesis.

Browse Gastroparesis studies →

Lead sponsor

Indiana University is the lead sponsor of 958 studies on the registry; 200 are open to participants now.

Of its 142 completed or terminated interventional studies of FDA-regulated products, 112 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All subjects 18 years and above who have a gastric electrical stimulator placed for gastroparesis

Inclusion criteria

  1. Gastroparetic patient with a stimulator (Enterra Device placed)
  2. Aged 18-80 years
  3. Willing to have electrodes placed on the neck

Exclusion criteria

Exclusion Criteria:

  1. Unable to provide consent
  2. Pregnant females
  3. Prisoners
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
45 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Optimal MEA configuration

    Identify the optimal MEA configuration for vagal response capture

    Time frame: 3 years

  2. GES and symptom survey

    Identify the compound nerve action potential in each subject and correlate that with the symptom survey data collected for each subject

    Time frame: 3 years

07

Study locations

1 site
  • Indiana University Hosptial
    Indianapolis, Indiana 46202, United States
08

References and documents

Study documents

  • Informed consent form · Jun 11, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

1 registry update since Sep 25, 2026
Status
Active, not recruiting→Completed
changed Sep 29, 2026
Primary completion
Aug 31, 2026→May 27, 2021 (actual)
Sep 29, 2026
Study completion
Aug 31, 2026→May 27, 2021 (actual)
Sep 29, 2026
Enrollment
40 (estimated)→45 (actual)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Active, not recruiting→Completed
    Primary completion Aug 31, 2026→May 27, 2021 (now actual)
    Study completion Aug 31, 2026→May 27, 2021 (now actual)
    Enrollment 40 (estimated)→45 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04207996
Lead sponsor
Indiana University
Collaborators
Purdue University
Responsible party
Thomas V. Nowak (Clinical Professor and Principal Investigator, Indiana University) — Principal investigator
First posted
Dec 23, 2019
Start date
Sep 1, 2019
Primary completion
May 27, 2021
Completion
May 27, 2021
Last update
Sep 29, 2026

Study contacts

Thomas V Nowak, MD
principal investigator · Indiana University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion